Sidansai
A Shanghai-based biotechnology company pioneering the advancement of cell therapy.
A Shanghai-based biotechnology company pioneering the advancement of cell therapy.
Sidansai is a Shanghai-based biotechnology company that has been making significant strides in the cell therapy industry since it was founded in 2009. The company, also known as Innovative Cellular Therapeutics Co.,Ltd., is committed to the research and development of innovative cell therapy technologies.
With a focus on biotechnology, health care, health and wellness, and marketing, Sidansai has established itself as a prominent player in the industry. Its latest milestone was the Series C investment it secured on 18 December 2019, with the notable investor being LH Ventures.
Sidansai’s dedication to pioneering the advancement of cell therapy makes it an intriguing prospect for venture capitalists seeking opportunities in the biotechnology and healthcare sectors. With a solid track record and a clear vision for the future, Sidansai has the potential to deliver significant returns for investors while also making a lasting impact on the field of cell therapy.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | Unknown | 1 |
|
18 Dec 2019 |
| Series B | $28.60M | 4 |
|
25 Apr 2018 |
We care about your data, and we'd love to use cookies make your experience better.
